A Type C meeting with the U.S. Food and Drug Administration (FDA) is a formal discussion that falls outside the A and B categories of FDA meeting types. It is designed for sponsors seeking clarification, guidance, or planning discussions on regulatory strategy and development plans that do not fit the predefined A or B meeting scopes. Understanding when to request a Type C meeting, how to prepare, and what to expect can help sponsors align with FDA expectations and streamline the regulatory path for a product under development.
Definition And Scope
A Type C meeting is part of the FDA’s meeting framework but is distinct from Type A and Type B meetings. Type C covers “other” meetings that involve substantive questions about regulatory expectations, development milestones, or data strategies that do not fit the precise criteria of A or B meetings. These meetings are often used for complex development programs, novel endpoints, or unique regulatory questions where flexibility is needed in planning and interpretation. The purpose is to gain FDA alignment on the right path forward and to address potential gaps before formal submission decisions are made.
When To Request A Type C Meeting
A Type C meeting is appropriate when a sponsor needs formal FDA input on topics such as regulatory strategy, endpoint selection, trial design concepts, or data package structure that aren’t covered by Type A or Type B discussions. Common scenarios include late-stage development questions, questions about resubmission timing after a rejection, or requests to discuss innovative approaches that require FDA interpretation. Meeting requests should be made when early, clear guidance could prevent wasted resources or misaligned expectations during later regulatory steps.
How To Request And Prepare
Submitting a Type C meeting request follows a formal process through the FDA’s meeting management system. The request should clearly articulate the questions, the background information, and the rationale for a live discussion. Preparation involves compiling a concise agenda, relevant data summaries, and a draft list of decision points sought from FDA. Include a proposed meeting format, preferred date ranges, and a plan for post-meeting follow-up. Providing context and prioritizing questions helps FDA staff prepare efficiently and increases the likelihood of meaningful, actionable guidance.
What Happens At The Meeting
During a Type C meeting, FDA reviewers and decision-makers review the sponsor’s questions, data, and strategic proposals. The meeting may be conducted in person or via teleconference, depending on logistics and regulatory requirements. FDA’s objective is to provide clear, actionable guidance that clarifies how to meet regulatory expectations and how to structure subsequent submissions. Outcomes typically include written meeting minutes summarizing agreed-upon points, recommended next steps, and any conditions or follow-up data requested by FDA.
Documentation And Follow-Up
Post-meeting, sponsors should receive FDA meeting minutes detailing decisions, clarifications, and suggested timelines. These minutes are essential for aligning internal teams and shaping the next regulatory steps, whether that involves protocol amendments, additional analyses, or revised submission plans. Sponsors should review the minutes for accuracy, circulate them to key stakeholders, and implement the agreed-upon actions. If discrepancies arise, a timely follow-up request to clarify points is advisable to prevent scope creep or misinterpretation.
Best Practices For A Successful Type C Meeting
- Be precise with questions: Prioritize a small number of essential, well-defined questions to maximize the value of the discussion.
- Provide context: Include concise background data and a clear rationale for each question to help FDA assess relevance quickly.
- Use a structured agenda: Propose a detailed agenda with time allocations to keep the meeting focused.
- Plan for follow-up: Identify data needs, analyses, or revised strategies anticipated after the meeting.
- Align internally: Ensure cross-functional teams (regulatory, clinical, statistics, quality) are aligned with the proposed path.
- Engage early: Consider requesting a Type C meeting early in a program when questions are broad or strategy-dependent.
Common Topics Addressed In Type C Meetings
- Regulatory strategy and overall development plan for a product candidate
- Endpoint selection, clinical trial design, and statistical considerations
- Data package structure for future submissions and labeling implications
- Clarification of regulatory expectations after a prior FDA action or feedback
- Post-approval commitments and real-world evidence considerations
Key Considerations For U.S. Sponsors
In the American market, Type C meetings can help harmonize regulatory expectations with development timelines, especially for innovative therapies and complex modalities. Clear documentation, a focused set of questions, and timely follow-up are critical to leveraging FDA guidance effectively. Companies should view Type C meetings as a strategic tool to de-risk development plans and optimize the pathway to approval or clearance.